Cp 3 - Rowe

Front 1

targeted vs non-targeted therapy

Back 1

targeted: know the target, drugs developed to selectively inhibit process specific to cancer

non: developed empirically, had effect on "cancer phenotype"

Front 2

examples of non-targeted cancer therapies

Back 2

5-FU, doxorubicin, cyclophosphamide

Front 3

advantages of targeted therapy (3)

Back 3

makes sense given cancer biology, effects of therapy can be tested based on effect on the target, mechanisms of drug-resistance can be more easily identified

Front 4

What are SERMs

Back 4

selective estrogen receptor modulators

Front 5

tamoxifen

Back 5

hormone ablation therapy for women with ER positive breast ca

Front 6

cetuximab

Back 6

antibody that targets epidermal growth factor receptor (EGFR) for the treatment of colorectal cancer

not effective in those with mutations in Ras, Raf (downstream of EGFR)

Front 7

trastuzamab/herceptin

Back 7

antibody that targets epidermal growth factor receptor (EGFR) for the treatment of breast cancer

not effective in those with mutations in Ras, Raf (downstream of EGFR)

Front 8

erlotinib

Back 8

EGFR tyrosine kinase inhibitor for treatment of non-small cell lung cancer

increased response in those with activating mutation in EGFR tyrosine kinase

Front 9

imantinib

Back 9

inhibits BCR-ABL and stops cell proliferation in CML

Front 10

what percentage of CML cases are caused by the philadelphia chromosome?

Back 10

95%

Front 11

vemurafenib

Back 11

mutations in BRAF found in 50% of melanomas and 90% of mutations affect single residue (V600E); mutation makes it constituitively active - activates MEK pathway; drug that blocks only constituitively active BRAF